Compositions and methods for inhibiting bacterial growth

Patent metadata

Field	Value
Publication number	US-10653679-B2
Application number	US-201615572121-A
Country	US
Kind code	B2
Filing date	May 4, 2016
Priority date	May 4, 2015
Publication date	May 19, 2020
Grant date	May 19, 2020

Abstract

The present disclosure provides, among other things, compositions and methods useful for inhibiting bacteria, such as Mycobacterium tuberculosis. These compositions and methods find many uses in medicine and research, e.g., treating subjects afflicted with active or latent bacterial infections. The compositions described herein are also useful for decontaminating surfaces (e.g., surgical tools or implants).

First claim

What is claimed is:

1. A method for treating a subject who is infected with bacterial cells in which the PhoPR regulon is conserved, the method comprising administering to the subject an effective amount of an inhibitor of the PhoPR regulon to thereby treat the infection, wherein the inhibitor of the PhoPR regulon is ethoxzolamide.

2. A method for ameliorating the signs or symptoms of an infection of a subject by bacterial cells in which the PhoPR regulon is conserved, the method comprising administering to the subject an effective amount of an inhibitor of the PhoPR regulon to thereby ameliorate the signs and symptoms of the infection, wherein the inhibitor of the PhoPR regulon is ethoxzolamide.

3. The method according to claim 1 , further comprising identifying the subject as having an infection with bacterial cells in which the PhoPR regulon is conserved.

4. The method according to claim 1 , wherein the bacteria or bacterial cells are selected from the group consisting of Mycobacterium, Mycobacterium tuberculosis , multi-drug resistant Mycobacterium tuberculosis , extensively drug resistant Mycobacterium tuberculosis , nontuberculosis mycobacterium (NTM), Clostridium, Bacillus, C. acetobutylicum, B. subtilis, Echerichia coli, Vibrio cholera, Streptomyces coelicolor , and Enterobacteriaceae.

5. The method according to claim 1 , wherein the inhibitor is orally administered, parenterally administered, intravenously administered, administered as an aerosol, administered using a nebulizer or inhaler, topically administered, administered as an eye drop, administered as a cream, an ointment, or a lotion, or present on a bandage or dressing applied to an infected site to the subject.

6. The method according to claim 1 , wherein the subject has a lung infection, skin infection, or eye infection.

7. A method according to claim 1 , wherein the subject is afflicted with tuberculosis, multi-resistant tuberculosis, or extensively multidrug resistant tuberculosis.

8. The method according to claim 1 , wherein the subject is a human.

9. The method according to claim 1 for eliminating dormant Mycobacterium tuberculosis cells in a subject afflicted with latent tuberculosis, the method comprising administering to the subject an effective amount of ethoxzolamide to thereby eliminate dormant Mycobacterium tuberculosis cells in the subject and treat latent tuberculosis.

10. The method according to claim 1 , wherein the effective amount of ethoxzolamide is between 0.01 and 100 mg/kg body weight of the subject.

11. The method according to claim 1 , wherein the ethoxzolamide is administered in combination with one or more antibiotics selected from the group consisting of isoniazid, rifampicin, ethambutol, and pyrazinamide.

12. The method according to claim 1 , wherein the ethoxzolamide is administered for less than 6 weeks or between 2 to 4 weeks.

13. The method according to claim 2 , further comprising identifying the subject as having an infection with bacterial cells in which the PhoPR regulon is conserved.

14. The method according to claim 2 , wherein the bacteria or bacterial cells are selected from the group consisting of Mycobacterium, Mycobacterium tuberculosis , multi-drug resistant Mycobacterium tuberculosis , extensively drug resistant Mycobacterium tuberculosis , nontuberculosis mycobacterium (NTM), Clostridium, Bacillus, C. acetobutylicum, B. subtilis, Echerichia coli, Vibrio cholera, Streptomyces coelicolor , and Enterobacteriaceae.

15. The method according to claim 2 , wherein the inhibitor is orally administered, parenterally administered, intravenously administered, administered as an aerosol, administered using a nebulizer or inhaler, topically administered, administered as an eye drop, administered as a cream, an ointment, or a lotion, or present on a bandage or dressing applied to an infected site to the subject.

16. The method according to claim 2 , wherein the subject has a lung infection, skin infection, or eye infection.

17. A method according to claim 2 , wherein the subject is afflicted with tuberculosis, multi-resistant tuberculosis, or extensively multidrug resistant tuberculosis.

18. The method according to claim 2 , wherein the subject is a human.

19. The method according to claim 2 , for eliminating dormant Mycobacterium tuberculosis cells in a subject afflicted with latent tuberculosis, the method comprising administering to the subject an effective amount of ethoxzolamide to thereby eliminate dormant Mycobacterium tuberculosis cells in the subject and treat latent tuberculosis.

20. The method according to claim 2 , wherein the effective amount of ethoxzolamide is between 0.01 and 100 mg/kg body weight of the subject.

21. The method according to claim 2 , wherein the ethoxzolamide is administered in combination with one or more antibiotics selected from the group consisting of isoniazid, rifampicin, ethambutol, and pyrazinamide.

22. The method according to claim 2 , wherein the ethoxzolamide is administered for less than 6 weeks or between 2 to 4 weeks.

Assignees

• Univ Michigan State

Inventors

• Abramovitch Robert
• Johnson Benjamin K
• Colvin Christopher J

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/428 Primary

  condensed with carbocyclic rings · CPC title

• A61P31/06

  for tuberculosis · CPC title

• Y02A50/473

  Cross-Sectional Technologies · mapped topic

• Y02A50/471

  Cross-Sectional Technologies · mapped topic